Analytical Data
-
Gene name
S1
- Application
-
Alternative Names
/
-
Species
Infectious bronchitis
-
Source
E. coli
-
Tag
N- GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
D9IAI3
-
Expression Region
231-539aa
-
Molecular Weight
61.7 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The S1 protein, a key component of various viruses, particularly coronaviruses, plays a crucial role in mediating viral entry into host cells. As the receptor-binding subunit of the spike (S) glycoprotein, S1 is responsible for recognizing and binding to host cell receptors, such as ACE2 in the case of SARS-CoV-2. Understanding the structure and function of the S1 protein is vital for vaccine development and therapeutic interventions. Research on S1 recombinant proteins has gained momentum due to their potential use in eliciting immune responses, providing insights into the mechanisms of viral pathogenesis, and enabling the design of inhibitors that block virus entry. In the context of the COVID-19 pandemic, the study of S1 proteins has accelerated, leading to the development of mRNA vaccines that induce an immune response against the S1 domain. This research is instrumental in the ongoing efforts to combat emerging viral infections, highlighting the importance of S1 as a target for diagnostic and therapeutic strategies. Overall, the investigation of S1 recombinant proteins contributes significantly to our understanding of viral biology and the development of effective vaccines and antiviral drugs.
